References
- Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl 1: S24–9.
- Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD. Heartburn, oesophagitis and Barrett's oesophagus in self- medicating patients in general practice. Br J Clin Pract 1996; 50: 245–8.
- Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 714–8.
- Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management: the Genval workshop report. Gut 1999; 44 Suppl 2: S1–16.
- Dent J, Hetzel DJ, MacKinnon MA, Reed WD, Narielvala FM. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol Suppl 1989; 166: S76–82; discussion 94.
- Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321–6.
- Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238–43.
- Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999; 13: 1611–20.
- Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 3071–80.
- Bate CM, Griffin SM, Keeling PW, Axon AT, Dronfield MW, Chapman RW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 547–55.
- Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974–9.
- Rohss K, Wilder-Smith C, Claar-Nilsson C, Lundin C. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120 Suppl 1: A-419.
- Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249–58.
- Castell DO, Kahrilas PJ, Richter JE, Johnson DA, Vakil NB, Zuckerman S, et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis (EO). Gut 2001; 49 Suppl III: S3363.
- Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
- Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in disease specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81–7.
- Weusten BL, Roelofs JM, Akkermans, Van Berge-Henegouwen GP, Smout AJ. The symptom-association probability: an improved method for symptom analysis of 24-h esophageal pH data. Gastroenterology 1994; 107: 1741–5.
- Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80.
- Johnsson F, Joelsson B, Isberg P-E. Ambulatory 24-h pH- monitoring in the diagnosis of gastroesophageal reflux disease. Gut 1987; 28: 1145.
- Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro- oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 15–20.